Keyword: Valeant Pharmaceuticals
Bausch Health is working to pay down debt and focusing on "organic growth," but one analyst says the company hasn't changed much from the old Valeant.
Bausch hopes it can turn around Synergy's struggling constipation drug Trulance to complement its own Xifaxan.
Though Cosmo's Aemcolo is now only approved in travelers' diarrhea, it could soon tap into Xifaxan's much larger IBS-D market, one analyst predicts.
Attorneys for both defendants, Valeant's former executive Gary Tanner and ex-Philidor CEO Andrew Davenport, say they'll appeal the convictions.
Perrigo CEO Uwe Roehrhoff is stepping down effective immediately, the company announced, to be replaced by former tobacco executive Murray Kessler.
After a meeting with the FDA, Bausch Health is back on track with psoriasis candidate Duobrii sooner than some analysts expected.
More and more postscandal drugmakers are landing on the same solution for restoring their good name: Change it.
What do you do when you need growth, and one drug is far and away your biggest? GIve that product as much fuel as possible.
US WorldMeds needed a partner to help launch its first-ever opioid withdrawal med Lucemyra, and Valeant’s Salix has taken the job.
Wells Fargo analyst depicted the rejection as “a major setback” for Valeant that puts a dent in the company’s five-year growth plan.